Anxiety is a result of a combination of biological, psychological, and other individual factors. Neurochemical imbalances in γ-aminobutyric acid (GABA), serotonin, dopamine, epinephrine, and other neurotransmitter pathways in the brain can contribute to the development of anxiety. For example, serotonin appears to be specifically involved in feelings of well-being, and disruption in this pathway is highly related to anxiety and depression.
Current treatments for anxiety are associated with adverse effects and have dependency and withdrawal issues. This has driven us to discover and develop the pharmaceutical formulation (MP-20X) containing natural and chemical API molecules, targeting the endocannabinoid system, offering great potential in the field of affective disorders.